REGN Regeneron Pharmaceuticals

XNGS Up Alert

Health Care

· How we analyze

About the company

Regeneron Pharmaceuticals is a US biotech company. It develops antibody drugs such as Eylea for eye diseases and, together with Sanofi, Dupixent for inflammatory diseases such as atopic dermatitis. It also does research on cancer and genetic diseases. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Tarrytown, USA

According to the company, it is a fully integrated biotechnology company that invents, develops, manufactures and markets medicines for people with serious diseases. The business forms a single segment. The therapeutic areas range from eye diseases and allergic and inflammatory diseases to cancer, cardiovascular and metabolic diseases and rare diseases. Approved products are aimed at wet age-related macular degeneration, asthma and certain forms of lung cancer, among other conditions. The company markets individual products together with partners or licensees.

Automatically summarized from SEC annual report (10-K, filed Feb 4, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Regeneron Pharmaceuticals

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +1.0%
  • 7 days +1.1%
  • 30 days +3.6%
  • 1 year +39.4%
Day range (last trading day)
−1.5%Price at 100% of the range0.0%
52-week range
−27.5%Price at 84% of the range+5.3%
Distance from the all-time high
−32.6%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NASDAQ:REGN

Fundamental analysis

Regeneron Pharmaceuticals · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 4, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 1 without data 6 of 7 criteria met Growth Revenue and earnings per share 6 of 7 criteria met Dividend Level, consistency, coverage · 4 without data 3 of 3 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 6 of 7 met · 1 without data

  • no data: Gross margin above 40% not stated in the SEC filings
  • met: Operating margin above 15% 24.9%
  • met: Net margin above 10% 31.4%
  • not met: Return on equity above 15% 14.4%
  • met: Free cash flow margin above 10% 28.4%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 77.1%
Operating margin

24.9% Fiscal year 2025

Rank 68 of 100: higher than 68% of 192 peers (All). strong.

Rank 78 of 100: higher than 78% of 20 peers (Sector). strong.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

31.4% Fiscal year 2025

Rank 87 of 100: higher than 87% of 237 peers (All). strong.

Rank 87 of 100: higher than 87% of 26 peers (Sector). strong.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

14.4% Fiscal year 2025

Rank 46 of 100: higher than 46% of 218 peers (All). medium.

Rank 55 of 100: higher than 55% of 21 peers (Sector). medium.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

11.1% Fiscal year 2025 (total assets at year end)

Rank 73 of 100: higher than 73% of 238 peers (All). strong.

Rank 67 of 100: higher than 67% of 26 peers (Sector). strong.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

77.1% Fiscal year 2025

Rank 93 of 100: higher than 93% of 239 peers (All). strong.

Rank 94 of 100: higher than 94% of 26 peers (Sector). strong.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

28.4% Fiscal year 2025

Rank 81 of 100: higher than 81% of 213 peers (All). strong.

Rank 90 of 100: higher than 90% of 25 peers (Sector). strong.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

4.1B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 6 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +5.6%
  • met: Over 5 years, revenue grew by more than 5% per year +11.0%
  • met: Over 10 years, revenue grew by more than 5% per year +13.3%
  • not met: Over 3 years, EPS grew by more than 5% per year +2.8%
  • met: Over 5 years, EPS grew by more than 5% per year +6.3%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +1.0%
Revenue growth 3 years

+5.6% per year

Rank 38 of 100: higher than 38% of 230 peers (All). medium.

Rank 50 of 100: higher than 50% of 25 peers (Sector). medium.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+11.0% per year

Rank 50 of 100: higher than 50% of 217 peers (All). medium.

Rank 58 of 100: higher than 58% of 25 peers (Sector). medium.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+13.3% per year

Rank 77 of 100: higher than 77% of 157 peers (All). strong.

Rank 76 of 100: higher than 76% of 19 peers (Sector). strong.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+2.8% per year

Rank 29 of 100: higher than 29% of 157 peers (All). weak.

Rank 43 of 100: higher than 43% of 22 peers (Sector). medium.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+6.3% per year

Rank 25 of 100: higher than 25% of 146 peers (All). weak.

Rank 43 of 100: higher than 43% of 20 peers (Sector). medium.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+22.3% per year

Rank 85 of 100: higher than 85% of 140 peers (All). strong.

Rank 93 of 100: higher than 93% of 20 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 3 of 3 met · 4 without data

  • met: Pays a dividend 3.52 USD
  • met: Payout ratio at most 60% of earnings 8%
  • no data: Dividend paid in each of the last 5 fiscal years not reported as an annual figure for each of the last 5 fiscal years
  • no data: Dividend per share never lowered in the last 5 fiscal years not reported as an annual figure for each of the last 5 fiscal years
  • no data: Dividend per share higher than 5 years ago no comparable dividend 5 years ago
  • met: Free cash flow per share covers the dividend 10.7x
  • no data: Dividends paid over the last 5 years covered by free cash flow dividends paid or free cash flow reported for fewer than 3 years
Payout ratio

8% Fiscal year 2025

Dividend per share divided by earnings per share.

Free cash flow coverage

10.7x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 5 of 8 · 1 without data
  • met: Long-term debt no higher than equity 0.06
  • met: Current assets cover current liabilities 4.13
  • met: Positive equity 31.3B USD
  • met: In 5 years, share count up by at most 5% −5.6%
  • met: Free cash flow positive in the last fiscal year 4.1B USD
Piotroski F-Score

5 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.06 at fiscal year end

Rank 91 of 100: lower than 91% of 199 peers (All). strong.

Rank 97 of 100: lower than 97% of 18 peers (Sector). strong.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

4.13 at fiscal year end

Rank 88 of 100: higher than 88% of 215 peers (All). strong.

Rank 90 of 100: higher than 90% of 26 peers (Sector). strong.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−5.6% in 5 years

Rank 65 of 100: lower than 65% of 199 peers (All). medium.

Rank 69 of 100: lower than 69% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • no data: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+11.0% per year), at least as fast as the sector median.
  • Light yellow: Net income (total) grew over 5 years (+5.1% per year), more slowly than the sector median; per share +6.3% per year.
  • Light green: Net margin 31.4%, above the sector median (12.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 4.9B USD · Net income 895.5M USD · Net margin 18.4%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 5.9B USD · Net income 1.2B USD · Net margin 20.4%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 6.7B USD · Net income 2.4B USD · Net margin 36.4%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 7.9B USD · Net income 2.1B USD · Net margin 26.9%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 8.5B USD · Net income 3.5B USD · Net margin 41.3%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 16.1B USD · Net income 8.1B USD · Net margin 50.2%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 12.2B USD · Net income 4.3B USD · Net margin 35.6%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 13.1B USD · Net income 4.0B USD · Net margin 30.1%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 14.2B USD · Net income 4.4B USD · Net margin 31.1%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 14.3B USD · Net income 4.5B USD · Net margin 31.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 14.3B USD · Net income 4.5B USD · Net margin 31.4%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 24.9 USD operating income and 31.4 USD net income remained.

Net income is above operating income (e.g. a tax benefit, gains on investments or securities).

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue14.3B USD100.0%
Operating income3.6B USD24.9%
Research & development5.9B USD40.8%
Remaining cost of revenue and operating expenses4.9B USD34.3%
Net income4.5B USD31.4%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 42.1% to 24.9%.

Operating marginNet margin
  1. Fiscal year 2016: Operating margin 27.4% · Net margin 18.4%
  2. Fiscal year 2017: Operating margin 35.4% · Net margin 20.4%
  3. Fiscal year 2018: Operating margin 37.8% · Net margin 36.4%
  4. Fiscal year 2019: Operating margin 28.1% · Net margin 26.9%
  5. Fiscal year 2020: Operating margin 42.1% · Net margin 41.3%
  6. Fiscal year 2021: Operating margin 55.7% · Net margin 50.2%
  7. Fiscal year 2022: Operating margin 38.9% · Net margin 35.6%
  8. Fiscal year 2023: Operating margin 30.9% · Net margin 30.1%
  9. Fiscal year 2024: Operating margin 28.1% · Net margin 31.1%
  10. Fiscal year 2025: Operating margin 24.9% · Net margin 31.4%

Returns

Return on equity fell in 5 years from 31.9% to 14.4%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 20.1% · Return on assets 12.8%
  2. Fiscal year 2017: Return on equity 19.5% · Return on assets 13.7%
  3. Fiscal year 2018: Return on equity 27.9% · Return on assets 20.8%
  4. Fiscal year 2019: Return on equity 19.1% · Return on assets 14.3%
  5. Fiscal year 2020: Return on equity 31.9% · Return on assets 20.5%
  6. Fiscal year 2021: Return on equity 43.0% · Return on assets 31.7%
  7. Fiscal year 2022: Return on equity 19.1% · Return on assets 14.9%
  8. Fiscal year 2023: Return on equity 15.2% · Return on assets 12.0%
  9. Fiscal year 2024: Return on equity 15.0% · Return on assets 11.7%
  10. Fiscal year 2025: Return on equity 14.4% · Return on assets 11.1%

Equity and long-term debt

The equity ratio rose in 5 years from 64.2% to 77.1%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 4.4B USD · Long-term debt not available
  2. Fiscal year 2017: Equity 6.1B USD · Long-term debt not available
  3. Fiscal year 2018: Equity 8.8B USD · Long-term debt not available
  4. Fiscal year 2019: Equity 11.1B USD · Long-term debt 0.0 USD
  5. Fiscal year 2020: Equity 11.0B USD · Long-term debt 2.0B USD
  6. Fiscal year 2021: Equity 18.8B USD · Long-term debt 2.0B USD
  7. Fiscal year 2022: Equity 22.7B USD · Long-term debt 2.0B USD
  8. Fiscal year 2023: Equity 26.0B USD · Long-term debt 2.0B USD
  9. Fiscal year 2024: Equity 29.4B USD · Long-term debt 2.0B USD
  10. Fiscal year 2025: Equity 31.3B USD · Long-term debt 2.0B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 3.63 to 4.13.

Current ratio
  1. Fiscal year 2016: Current ratio 2.56
  2. Fiscal year 2017: Current ratio 3.82
  3. Fiscal year 2018: Current ratio 4.47
  4. Fiscal year 2019: Current ratio 3.67
  5. Fiscal year 2020: Current ratio 3.63
  6. Fiscal year 2021: Current ratio 3.56
  7. Fiscal year 2022: Current ratio 5.06
  8. Fiscal year 2023: Current ratio 5.69
  9. Fiscal year 2024: Current ratio 4.73
  10. Fiscal year 2025: Current ratio 4.13

Cash flow

Free cash flow rose in 5 years from 2.0B USD to 4.1B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 1.5B USD · Capital expenditure 511.9M USD · Free cash flow 961.5M USD
  2. Fiscal year 2017: Operating cash flow 1.3B USD · Capital expenditure 272.6M USD · Free cash flow 1.0B USD
  3. Fiscal year 2018: Operating cash flow 2.2B USD · Capital expenditure 383.1M USD · Free cash flow 1.8B USD
  4. Fiscal year 2019: Operating cash flow 2.4B USD · Capital expenditure 429.6M USD · Free cash flow 2.0B USD
  5. Fiscal year 2020: Operating cash flow 2.6B USD · Capital expenditure 614.6M USD · Free cash flow 2.0B USD
  6. Fiscal year 2021: Operating cash flow 7.1B USD · Capital expenditure 551.9M USD · Free cash flow 6.5B USD
  7. Fiscal year 2022: Operating cash flow 5.0B USD · Capital expenditure 590.1M USD · Free cash flow 4.4B USD
  8. Fiscal year 2023: Operating cash flow 4.6B USD · Capital expenditure 718.6M USD · Free cash flow 3.9B USD
  9. Fiscal year 2024: Operating cash flow 4.4B USD · Capital expenditure 755.9M USD · Free cash flow 3.7B USD
  10. Fiscal year 2025: Operating cash flow 5.0B USD · Capital expenditure 898.4M USD · Free cash flow 4.1B USD

Share count

The share count fell in 5 years by 5.6% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 116.4M
  2. Fiscal year 2017: Diluted share count 116.0M
  3. Fiscal year 2018: Diluted share count 114.8M
  4. Fiscal year 2019: Diluted share count 114.6M
  5. Fiscal year 2020: Diluted share count 115.1M
  6. Fiscal year 2021: Diluted share count 112.2M
  7. Fiscal year 2022: Diluted share count 113.5M
  8. Fiscal year 2023: Diluted share count 113.7M
  9. Fiscal year 2024: Diluted share count 115.1M
  10. Fiscal year 2025: Diluted share count 108.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.52 USD · Fiscal year 2025
Dividend growth per year
3 y –5 y –10 y –
Years without a cut
0 as far as the data goes
Payout ratio
of earnings 8% of free cash flow 9%
To shareholders (5 years)
12.4B USD 97% through repurchases
Share count over 5 years
−5.6% fewer shares – each share is a larger stake

Dividend per share

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share not available
  2. Fiscal year 2017: Dividend per share not available
  3. Fiscal year 2018: Dividend per share not available
  4. Fiscal year 2019: Dividend per share not available
  5. Fiscal year 2020: Dividend per share not available
  6. Fiscal year 2021: Dividend per share not available
  7. Fiscal year 2022: Dividend per share not available
  8. Fiscal year 2023: Dividend per share not available
  9. Fiscal year 2024: Dividend per share not available
  10. Fiscal year 2025: Dividend per share 3.52 USD

Payout ratios

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  2. Fiscal year 2017: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  3. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  4. Fiscal year 2019: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  6. Fiscal year 2021: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  7. Fiscal year 2022: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  8. Fiscal year 2023: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  9. Fiscal year 2024: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  10. Fiscal year 2025: Payout ratio (earnings) 8.5% · Payout ratio (free cash flow) 9.1%

What goes back to shareholders

Over 5 years, 12.4B USD went back to shareholders, 97% of it through share repurchases. That is 55% of the free cash flow of those years. This was offset by new shares issued for 6.4B USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 126.7M USD · Free cash flow 961.5M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 240.2M USD · Free cash flow 1.0B USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 4.4M USD · New shares issued (including employee plans) 114.5M USD · Free cash flow 1.8B USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 275.9M USD · New shares issued (including employee plans) 211.8M USD · Free cash flow 2.0B USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 5.8B USD · New shares issued (including employee plans) 2.6B USD · Free cash flow 2.0B USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 1.6B USD · New shares issued (including employee plans) 1.7B USD · Free cash flow 6.5B USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 2.1B USD · New shares issued (including employee plans) 1.5B USD · Free cash flow 4.4B USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 2.2B USD · New shares issued (including employee plans) 1.1B USD · Free cash flow 3.9B USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 2.6B USD · New shares issued (including employee plans) 1.5B USD · Free cash flow 3.7B USD
  10. Fiscal year 2025: Dividends paid 370.3M USD · Share repurchases 3.4B USD · New shares issued (including employee plans) 635.9M USD · Free cash flow 4.1B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Regeneron Pharmaceuticals next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison REGN, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals this stock 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+11.0% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 11.0% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+5.1% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +6.3% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 5.1% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

31.4% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 31.41 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 41.3%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.06 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.06 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
14.3B USD
Revenue vs. prior year
+1.0%
Net income (FY)
4.5B USD
Net income vs. prior year
+2.1%
EPS (FY)
41.48 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
−1
Shares held vs. prior quarter
−100.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 4, 2026 · Balance sheet Jun 30, 2026 (filed Jul 30, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 14.3B4.5B 31.4% 41.48 – –
2024Dec 31, 2024 14.2B4.4B 31.1% 38.34 – –
2023Dec 31, 2023 13.1B4.0B 30.1% 34.77 – –
2022Dec 31, 2022 12.2B4.3B 35.6% 38.22 – –
2021Dec 31, 2021 16.1B8.1B 50.2% 71.97 – –
2020Dec 31, 2020 8.5B3.5B 41.3% 30.52 – –
2019Dec 31, 2019 7.9B2.1B 26.9% 18.46 – –
2018Dec 31, 2018 6.7B2.4B 36.4% 21.29 – –
2017Dec 31, 2017 5.9B1.2B 20.4% 10.34 – –
2016Dec 31, 2016 4.9B895.5M 18.4% 7.70 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 4.3B1.3B 30.2% 12.23 0.94 8%
Q1/26Mar 31, 2026 3.6B727.2M 20.2% 6.75 0.94 14%
Q4/25*Dec 31, 2025 3.9B844.6M 21.7% – 0.88 –
Q3/25Sep 30, 2025 3.8B1.5B 38.9% 13.62 0.88 6%
Q2/25Jun 30, 2025 3.7B1.4B 37.9% 12.81 0.88 7%
Q1/25Mar 31, 2025 3.0B808.7M 26.7% 7.27 0.88 12%
Q4/24*Dec 31, 2024 3.8B917.7M 24.2% – – –
Q3/24Sep 30, 2024 3.7B1.3B 36.0% 11.54 – –
Q2/24Jun 30, 2024 3.5B1.4B 40.4% 12.41 – –
Q1/24Mar 31, 2024 3.1B722.0M 23.0% 6.27 – –
Q4/23*Dec 31, 2023 3.4B1.2B 33.8% – – –
Q3/23Sep 30, 2023 3.4B1.0B 30.0% 8.89 – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $6.5M4 people −$6.5M
6 months $00 people $6.7M5 people −$6.7M
12 months $00 people $16.1M8 people −$16.1M

Latest transactions

  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 50 shares · $39.1K · SEC
  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 463 shares · $361.4K · SEC
  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 380 shares · $296.2K · SEC
  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 454 shares · $353.5K · SEC
  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 38 shares · $29.6K · SEC
  • Oct 14, 2026 Murphy Andrew J Officer Open-market sale · 10b5-1 plan 66 shares · $51.2K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +55

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)22.2
Rel. strength 60 d+6.4%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on REGN yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: REGN

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close